BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of $0.80 per ADS and accompanying warrant. Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx. The warrants will have an exercise price of $0.80 per ADS, will be exercisable at any time upon issuance and will expire five years from the date of issuance. The offering is expected to close on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
BioLinerX Ltd.（納斯達克股票代碼：BLRX）（TASE：BLRX）（“BioLinerX” 或 “公司”）是一家致力於改變生命的腫瘤和罕見疾病療法的商業階段生物製藥公司，今天宣佈，它已與幾家機構投資者簽訂了最終協議，以註冊直接發行的形式發行和出售該公司750萬股美國存托股份（ADS）和認股權證持有人總共購買最多7,500,000份美國存託憑證，每份ADS和附帶的認股權證的總購買價格爲0.80美元。每股ADS代表BioLinerX的十五（15）股普通股，面值爲每股0.10新謝克爾。認股權證的行使價爲每份ADS0.80美元，可在發行後隨時行使，並將自發行之日起五年內到期。此次發行預計將於2024年4月1日左右結束，但須滿足慣例成交條件。
The gross proceeds from the offering (without taking into account any proceeds from any future exercises of warrants), before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be $6.0 million. BioLineRx intends to use the net proceeds from the offering to support the commercialization of APHEXDA (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in patients with multiple myeloma, advance its pancreatic cancer clinical development program and other pipeline programs, and for general corporate purposes.
在扣除配售代理費和公司應付的其他發行費用之前，此次發行的總收益（不考慮未來行使認股權證的任何收益）預計爲600萬美元。BioLinerX打算將此次發行的淨收益用於支持APHEXDA（motixafortide）的商業化，其在美國的適應症是用於多發性骨髓瘤患者自體移植的幹細胞動員，推進其胰腺癌臨床開發計劃和其他管道項目，以及用於一般公司用途。
"We believe that today's equity transaction, when combined with the potential drawdown of an additional $20 million tranche from our existing debt facility at favorable interest rates, together with our existing cash, provides the Company with the financial resources to continue building our momentum with the APHEXDA launch and advancing key life cycle programs for long-term growth opportunities", said Philip Serlin, Chief Executive Officer of BioLineRx.
BioLinerX首席執行官菲利普·塞林表示：“我們認爲，今天的股權交易，加上可能以優惠利率從現有債務融資中再提取2000萬美元，再加上我們現有的現金，爲公司提供了財政資源，使APHEXDA的啓動和推進關鍵生命週期計劃以獲得長期增長機會。”
JonesTrading Institutional Services LLC is acting as the exclusive placement agent for the offering.
JoneStrading機構服務有限責任公司是本次發行的獨家配售代理。
譯文內容由第三人軟體翻譯。